Moffitt Cancer Center
Biden Cancer Moonshot Announces New Projects Focused on Decreasing Cancer Burden in Africa
Programs aim to improve screening tools and adherence, advance new point-of-care diagnostics, and increase access to precision medicine on the continent.
Foundation Medicine Monitoring Assays Show Promise for Guiding Lung Cancer Chemo-Immunotherapy
Premium
Investigators showed that patients who are positive for ctDNA at the time of their fourth induction treatment have poorer outcomes and could benefit from new strategies.
Clarified Precision Medicine Acquires Molecular Diagnostics Firm Interpares Biomedicine
The acquisition brings Interpares' genetic sequencing test, OncoGuardian, into Clarified's portfolio of precision medicine products.
Apis Assay Technologies, Moffitt Cancer Center to Evaluate RNA Biomarkers for Cancer Progression
The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.
Blood-Based Genetic Risk Score Shows Promise for Prostate Cancer Drug Response, Survival Prediction
Premium
The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.